Prieto 2006.

Methods	Randomised, double‐blind, parallel‐group, placebo‐controlled trial
Participants	N = 34. Mean age unclear. Treatment group: 18; control group: 16 Inclusion criteria: mild to moderate allergic asthma
Interventions	Subcutaneous omalizumab versus placebo (dosage unclear) Treatment lasted for 12 weeks
Outcomes	Airway responsiveness
Notes	Unpublished conference abstract: Jadad score: 2
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Details of sequence generation not included in trial report
Allocation concealment (selection bias)	Unclear risk	Details of allocation concealment not included in trial report
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Five participants did not complete the trial, and reasons for withdrawal are included in the trial report
Selective reporting (reporting bias)	Unclear risk	No apparent indication of selective reporting bias